Rubicon Research Limited — Q2 FY26 earnings call

Call held 13 Nov 2025

Management summary

Rubicon Research reported a strong Q2 FY26, marking its first earnings call post-IPO with impressive growth across key financial metrics. The performance was driven by a combination of new launches and sustained momentum in its specialty product portfolio, which now accounts for nearly a third of gross profit. Management outlined a clear strategy focused on R&D, with a sustained investment of 10-11% of revenue guided for the next five years, targeting complex areas like neurology and drug-device combinations. While current manufacturing constraints are impacting gross margins, the upcoming Pithampur facility is set to alleviate this pressure from mid-2026.

Highlights

  • Revenue grew by 39% YoY, driven by new launches and growth in existing products.

  • Operating EBITDA increased by 53% YoY, with the margin standing at 22.9%.

  • PAT saw a significant 56% YoY growth.

  • Specialty products contributed 32.5% to the total gross profit for the quarter.

  • Annualized ROACE for the quarter stood at a strong 36%.

  • R&D expenditure was 11.2% of operating revenue, with guidance to maintain it at 10-11% for the next 5 years.

  • Cash flow from operations was robust at 605 million INR.

  • The Pithampur facility is expected to be operational by mid-2026 to address manufacturing capacity constraints.

Key financials

  1. Revenue Growth 39%
  2. Operating EBITDA Growth 53%
  3. PAT Growth 56%
  4. EBITDA Margin 22.9%
  5. Gross Margin 68.7%
  6. R&D Spend 11.2 % of revenue
  7. Annualized ROACE 36%

What they filed

Q1 FY27: revenue up 54.0%, net profit up 134.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue255 245 301 278 336 +32%302 +23%390 +30%428 +54%
EBITDA68 64 61 63 79 +16%62 −3%106 +74%125 +98%
Net profit43 38 40 35 46 +7%37 −3%70 +75%82 +134%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Specialty Products
    32.5% Contribution to Gross Profit

Guidance & targets

Profitability

  • R&D Spend as % of Revenue Profitability · next 5 years · High confidence 10-11%
    Over 5 years.

    — Parag Sancheti, CEO

Margin

  • EBITDA Margin Margin · Near term · Medium confidence Sustain at current levels (~22.9%)
    Our EBITDA margin is expected to sustain at current levels...

    — Nitin Jajodia, CFO

  • Gross Margin Margin · Near term (until Pithampur ramps up) · Medium confidence Trend towards 68%
    ...even as GM trends towards 68% driven by hard outsource manufacturing as well as our revenue ramps up.

    — Nitin Jajodia, CFO

Capacity

  • Pithampur Plant Operationalization Capacity · Mid-2026 · High confidence Start taking batches
    So that's the reason we said we'll operationalize means we'll be in a position to take batches by the, in middle of 2026.

    — Parag Sancheti, CEO

Risks & concerns

  • Manufacturing capacity constraints

    medium

    Current capacity limitations are forcing increased reliance on outsourced manufacturing, which is putting pressure on gross margins (guided towards 68%).

    Management acknowledged

  • Pithampur plant regulatory approval timeline

    medium

    While the plant is expected to be operational by mid-2026, management explicitly stated they don't know the exact course of action the US FDA will take for approvals, introducing an element of uncertainty.

    Management acknowledged

  • Opaqueness on pipeline and strategic investments

    low

    Management refused to provide specifics on the pipeline split (generic vs. specialty) and the rationale for recent minority stake acquisitions, citing competitive reasons.

    Analyst deflected

Areas of evasion (2)

  • Specific split of pipeline between generics and specialty
  • Rationale and details of recent minority stake acquisitions

Q&A highlights

2 direct, 1 evasive
API integration strategy Direct
And just to add to that, what I said earlier, I think we don't subscribe to the view that the formulations business can be built by API integration. So from that, we are very, very clear that what we have done, current performance or the future performance is not dependent on API integration.

This clarifies a core part of their business strategy, confirming they are a pure-play formulations company with no plans for vertical integration into APIs.

Asked by Siddharth

Sustainability of R&D spend guidance Direct
Over 5 years.

Management provided a clear and long-term commitment to maintaining a high R&D spend (10-11% of sales), signaling that innovation is central to their long-term growth strategy.

Asked by Tushar

Rationale for recent minority stake acquisitions Evasive
Both are related to our pipeline strategy. And as Parag pointed out earlier on the call, you know, we will -- it will always be our sort of approach not to talk about specifics related to the pipeline. But, you know, at the appropriate time, we would disclose once approvals are received and so on.

Management deliberately withheld details on recent capital allocation decisions, linking them to a confidential pipeline strategy. This highlights an area of information asymmetry for investors.

Asked by Madhav

2 min read 6 chapters

Detailed narrative

Stellar Q2 Performance Driven by Broad-Based Growth

Rubicon Research reported a robust Q2 FY26 with revenue growing 39% YoY, Operating EBITDA up 53% YoY, and PAT surging 56% YoY. Management attributed this strong performance to a combination of new product launches and sustained growth in products launched 1.5-2 years ago. The company's growth is becoming more diversified, with the contribution of the top 10 products to revenue reducing from 56% to 51% compared to the previous quarter.

Specialty Products Emerge as a Key Profitability Driver

The company's strategic focus on specialty products is yielding significant results. These products, defined as having zero or one competitor for at least a year post-launch, contributed 32.5% of the total gross profit in Q2. This marks a substantial increase from their 13% contribution in the full fiscal year 2023, highlighting a successful shift in product mix towards higher-margin, less competitive assets.

Sustained R&D Investment to Fuel Future Growth

Management reiterated its commitment to innovation, guiding for R&D expenditure to remain in the 10-11% range of operating revenue for the next five years. The company is moving up the value chain, focusing on complex generics, a branded platform targeting CNS (neurology and neuro-rare diseases), and drug-device combinations like nasal sprays. This sustained investment underscores their strategy to build a pipeline of differentiated products.

Pithampur Plant to Address Manufacturing Constraints

Current manufacturing capacity constraints have led to increased reliance on outsourced manufacturing, which has contained the gross margin at 68.7%. To address this, the company acquired a third facility in Pithampur, which is expected to be operational and start taking batches by mid-2026. This facility has capabilities for oral solids, steroids, hormones, and topicals, and its ramp-up through Q1 CY27 is critical to improving margins and supporting future growth.

Proactive Compliance and Regulatory Excellence

Management emphasized a strong, proactive compliance culture as a key differentiator. They highlighted their voluntary participation in the FDA's new Quality Maturity Model program, being one of only eight companies selected globally for the pilot. This, combined with successfully clearing a surprise FDA audit at their Ambernath site, showcases a robust quality system that de-risks their operations in regulated markets.

Strategic Focus on Drug-Device Combinations

Rubicon has established end-to-end capabilities in drug-device combinations, particularly nasal sprays. Since starting development in late 2020, the company has secured five U.S. FDA approvals for intranasal spray products. This initiative is supported by a dedicated development center in Toronto and a manufacturing facility in Ambernath, positioning them in the high-value 'nose-to-brain' therapeutic space.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls